Sep 2026· Frontiers in Medical Technology· Vol 8· 0 citations· 46 references
Medicine
TL;DR
Overall, foundation models combined with weakly supervised learning provide competitive performance for BRAF status prediction in melanoma WSIs, but the findings highlight the need for diverse melanoma datasets and the importance of evaluating model performance beyond a single metric when developing H&E-based computational biomarkers.
Abstract
Introduction Melanoma is the most aggressive form of skin cancer, with around 40–50% of cases harbouring BRAF mutations that can be effectively targeted to improve patient outcomes. Typically, BRAF mutations are identified through DNA sequencing, which can be costly and contribute significantly to turn-around-times. Predicting BRAF status directly from haematoxylin and eosin (H&E) whole-slide images (WSIs) could offer a faster and more accessible alternative within digital pathology workflows. Methods In this study, we evaluated six pathology foundation models for WSI-based BRAF mutation prediction using an attention-based multiple instance learning (ABMIL) framework. Training and testing models with five-fold cross-validation, using 1,109 WSIs from 745 patients and performing external validation with TCGA and VisioMel cohorts. Results Models which utilised H-Optimus-1 features achieved the highest AUROC values on the internal test set (0.80 (0.72, 0.88)) and VisioMel (0.79 (0.75, 0.83) external test set, while UNI2-h features demonstrated superior sensitivity and higher TCGA performance (AUROC: 0.76 (0.66, 0.86)). Subgroup analyses indicated that model performance was impacted by histopathological features such as ulceration and tissue area, while t-SNE plots showed that high-attention foundation model features tended to cluster based on the dataset the features were from, rather than biological signal. Discussion Overall, foundation models combined with weakly supervised learning provide competitive performance for BRAF status prediction in melanoma WSIs, but our findings highlight the need for diverse melanoma datasets and the importance of evaluating model performance beyond a single metric when developing H&E-based computational biomarkers.
Deep learning applied to routine H&E WSIs can infer BRAF mutation status in cutaneous melanoma with consistent performance across institutional and external cohorts, but is not suitable for rule-out use or for deferring/omitting molecular testing.
Jiao-Jie Lv, Zheng Liu, Xue-Bing Jiang et al.· Journal of Clinical Patholog...· 0 citations
It is suggested that deep learning models, particularly Inception V3, can effectively predict TMB status in patients using histopathological images, and the potential for integrating DL techniques in clinical settings to enhance personalized treatment strategies for patients with varying TMB is highlighted.
T. A. Serel, Onur Ertunç, M. Kıran et al.· OBM Genetics· 0 citations
Molecular profiling tests currently relies significantly on genomics or transcriptomics analysis, leading a prolonged turnaround time and higher costs procedure. This comprehensive pan-cancer study aims to develop a general, weakly supervised, and clinically interpretable deep learning (DL) approach for predictin...
Hao-Ran Xi, Xiao-Bing Feng, Ye Lu et al.· BMC Medical Imaging· 0 citations
Background/Objectives: Adult-type diffuse gliomas (ADGs) are aggressive brain tumors with highly variable clinical outcomes. Prognostic assessment directly from routine hematoxylin and eosin (H&E)-stained whole-slide images (WSIs) could support personalized decision-making. Methods: To our knowledge, this is the first...
S. Innani, Carla Pitarch-Abaigar, Marwan M. Majeed et al.· Cancers· 0 citations
From a molecular perspective, colorectal cancer is a heterogeneous disease in which microsatellite instability (MSI) phenotypes, mismatch repair (MMR) status, chromosomal instability, or mutations in BRAF, KRAS, NRAS, and TP53 can influence prognosis, hereditary cancer risk assessment, and therapeutic approaches. Conve...
Marius Florentin Popa, Paul Șiancu, C. Mohor et al.· International Journal of Mol...· 0 citations
INTRODUCTION
Breast cancer is a heterogeneous malignancy comprising distinct molecular subtypes, each with varying therapeutic strategies and prognoses. Conventional molecular subtyping relies on immunohistochemistry and in situ hybridization studies, which may not be universally accessible due to financial and technic...
Mehdi Zarei, M. Arabfard, Mehdi Raei et al.· Cancer Treatment and Researc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.